JP2023508469A5 - - Google Patents

Info

Publication number
JP2023508469A5
JP2023508469A5 JP2022539383A JP2022539383A JP2023508469A5 JP 2023508469 A5 JP2023508469 A5 JP 2023508469A5 JP 2022539383 A JP2022539383 A JP 2022539383A JP 2022539383 A JP2022539383 A JP 2022539383A JP 2023508469 A5 JP2023508469 A5 JP 2023508469A5
Authority
JP
Japan
Prior art keywords
compound
disorders
composition
anxiety
depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022539383A
Other languages
English (en)
Japanese (ja)
Other versions
JP7644122B2 (ja
JP2023508469A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/067235 external-priority patent/WO2021134086A1/en
Publication of JP2023508469A publication Critical patent/JP2023508469A/ja
Publication of JP2023508469A5 publication Critical patent/JP2023508469A5/ja
Priority to JP2025029197A priority Critical patent/JP2025090628A/ja
Application granted granted Critical
Publication of JP7644122B2 publication Critical patent/JP7644122B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022539383A 2019-12-26 2020-12-28 アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用 Active JP7644122B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025029197A JP2025090628A (ja) 2019-12-26 2025-02-26 アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962953611P 2019-12-26 2019-12-26
US62/953,611 2019-12-26
US202063037044P 2020-06-10 2020-06-10
US63/037,044 2020-06-10
US202063093830P 2020-10-20 2020-10-20
US63/093,830 2020-10-20
PCT/US2020/067235 WO2021134086A1 (en) 2019-12-26 2020-12-28 Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025029197A Division JP2025090628A (ja) 2019-12-26 2025-02-26 アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用

Publications (3)

Publication Number Publication Date
JP2023508469A JP2023508469A (ja) 2023-03-02
JP2023508469A5 true JP2023508469A5 (enExample) 2023-12-20
JP7644122B2 JP7644122B2 (ja) 2025-03-11

Family

ID=74195194

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022539383A Active JP7644122B2 (ja) 2019-12-26 2020-12-28 アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用
JP2025029197A Pending JP2025090628A (ja) 2019-12-26 2025-02-26 アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025029197A Pending JP2025090628A (ja) 2019-12-26 2025-02-26 アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用

Country Status (10)

Country Link
US (2) US11344510B2 (enExample)
EP (1) EP4081301A1 (enExample)
JP (2) JP7644122B2 (enExample)
KR (1) KR20220131520A (enExample)
CN (2) CN119241381A (enExample)
AU (1) AU2020415511A1 (enExample)
CA (1) CA3165903A1 (enExample)
IL (1) IL294202A (enExample)
MX (1) MX2022007994A (enExample)
WO (1) WO2021134086A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE056378T2 (hu) 2013-09-13 2022-02-28 Univ Chiba Nat Univ Corp R-Ketamin és sójának alkalmazása gyógyszerekként
US11980595B2 (en) 2018-02-15 2024-05-14 National University Corporation Chiba University Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
WO2019213551A1 (en) 2018-05-04 2019-11-07 Perception Neuroscience, Inc. Methods of treating substance abuse
CN119241381A (zh) 2019-12-26 2025-01-03 吉尔伽美什制药公司 芳基环己基胺衍生物及其在精神障碍的治疗中的用途
KR20260008838A (ko) 2020-02-18 2026-01-16 길가메쉬 파마슈티컬스, 인코포레이티드 기분 장애 치료에 사용되기 위한 특이적 트립타민
WO2022248621A1 (en) 2021-05-25 2022-12-01 Awakn Ls Europe Holdings Limited Ketamine the treatment of behavioural addictions
CA3225353A1 (en) * 2021-06-25 2022-12-29 Gilgamesh Pharmaceuticals, Inc. Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders
CN118401239A (zh) * 2021-10-18 2024-07-26 克力迈医药公司 用于治疗抑郁症，包括难治性抑郁症的2-氟脱氯氯胺酮
US20250161264A1 (en) * 2022-02-11 2025-05-22 Gilgamesh Pharmaceuticals, Inc. (ampar-pam)-nmda receptor antagonist combination therapy for treatment of mental conditions and disorders
CN115677444A (zh) * 2022-10-26 2023-02-03 公安部第三研究所 同位素毒品代谢物标记化合物及其制备方法、用途
CN120858088A (zh) * 2022-12-28 2025-10-28 吉尔伽美什制药公司 2-苯基-2-氨基-环己-1-酮衍生物的合成
US12396981B2 (en) 2023-03-09 2025-08-26 William Shulman Methods of using DMT
CN121311461A (zh) * 2023-06-05 2026-01-09 吉尔伽美什制药公司 2-苯基-2-氨基环己-1-酮衍生物的结晶盐
US12129234B1 (en) 2023-08-03 2024-10-29 Gilgamesh Pharmaceuticals, Inc. Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
US12180158B1 (en) 2023-08-03 2024-12-31 Gilgamesh Pharmaceuticals, Inc. Crystalline fumarate salts of n-ethyl-2-(5-fluoro-1H-indol-3-yl)-n-methylethan-1-amine

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB853775A (en) 1957-09-19 1960-11-09 Parke Davis & Co Pharmaceutical compositions and methods for producing phenylcyclohexane compounds
DE1668550A1 (de) * 1967-09-19 1971-07-22 Parke Davis & Co 2-Alkoxyalkylamino-2-phenylcyclohexanonverbindungen und ihre Saeure-Additionssalze und Verfahren zu ihrer Herstellung
CA1100516A (en) 1976-06-03 1981-05-05 Daniel Lednicer 4-amino-4-arylcyclohexanones and their ketals
CA1105938A (en) 1976-06-03 1981-07-28 Daniel Lednicer 4-amino-4-arylcyclohexanone ketals
US4065573A (en) 1976-06-03 1977-12-27 The Upjohn Company 4-Amino-4-phenylcyclohexanone ketal compositions and process of use
ES2276109T3 (es) 2002-06-21 2007-06-16 Suven Life Sciences Limited Nuevos indoles arilcarbonilicos tetraciclicos que tienen afinidad por el receptor de serotonina, utiles como agentes terapeuticos, proceso para su preparacion y mezclas farmaceuticas que los contienen.
DK1523486T3 (da) 2002-06-21 2008-03-03 Suven Life Sciences Ltd Tetracykliske arylsulfonylindoler med serotoninreceptor-affinitet
DE60329607D1 (de) 2002-06-21 2009-11-19 Suven Life Sciences Ltd Sich als therapeutische mittel eignende arylalkylindole mit affinität für den serotoninrezeptor, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
DE10252666A1 (de) 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10360793A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
CA2618888A1 (en) 2005-08-10 2007-02-15 Bayer Schering Pharma Aktiengesellschaft Acyltryptophanols for fertility control
WO2008071455A1 (en) 2006-12-15 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Bicyclic acyltryptophanols
EP1956016A1 (en) 2006-12-15 2008-08-13 Bayer Schering Pharma Aktiengesellschaft Bicyclic acyltryptophanols
JP5599774B2 (ja) 2008-03-27 2014-10-01 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ヒドロキシメチルシクロヘキシルアミン類
AU2010203461A1 (en) 2009-01-09 2011-07-28 President And Fellows Of Harvard College Fluorine containing compounds and methods of use thereof
EP2435043A1 (en) 2009-05-27 2012-04-04 Université Libre de Bruxelles 3-alkyl-5-fluoroindole derivatives as myeloperoxidase inhibitors
TWI582092B (zh) 2010-07-28 2017-05-11 歌林達股份有限公司 順式－四氫－螺旋（環己烷－１,１’－吡啶［３,４－b］吲哚）－４－胺－衍生物
CN104276993B (zh) 2013-07-12 2019-03-15 广东东阳光药业有限公司 吲哚衍生物及其在药物上的应用
US20180021326A1 (en) 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
CA3052974A1 (en) 2017-02-09 2018-08-16 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative
GB201808150D0 (en) 2018-05-18 2018-07-11 Small Pharma Ltd Therapeutic compounds
GB201716942D0 (en) 2017-10-16 2017-11-29 Small Pharma Ltd Therapeutic compounds
MA50786A (fr) 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
EP3505509A1 (en) 2017-12-29 2019-07-03 Université de Liège Methods for the preparation of arylcycloalkylamine derivatives
US11980595B2 (en) 2018-02-15 2024-05-14 National University Corporation Chiba University Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
CN110343050B (zh) 2018-04-04 2021-09-24 上海键合医药科技有限公司 芳香类化合物及其制备方法和用途
KR102104953B1 (ko) * 2018-04-17 2020-04-27 삼육대학교 산학협력단 신규 케타민 유도체 및 이의 우울증의 예방 또는 치료 용도
TW202026281A (zh) 2018-12-12 2020-07-16 西班牙商艾斯提夫製藥股份有限公司 用於治療疼痛和疼痛相關病症之新吡咯啶–2– 甲酸衍生物
CA3132731A1 (en) 2019-03-07 2020-09-10 University Of Padova Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
CN119241381A (zh) * 2019-12-26 2025-01-03 吉尔伽美什制药公司 芳基环己基胺衍生物及其在精神障碍的治疗中的用途
CN112174851A (zh) 2020-11-09 2021-01-05 广州万孚生物技术股份有限公司 一种氟胺酮半抗原、氟胺酮抗原及其制备方法和应用
CN113234036B (zh) 2021-05-12 2023-07-14 斯莱普泰(上海)生物医药科技有限公司 Nmda受体拮抗剂及其用途

Similar Documents

Publication Publication Date Title
JP2023508469A5 (enExample)
KR100720290B1 (ko) 부프로피온 대사물, 이들의 합성방법 및 사용방법
JP2012521994A5 (enExample)
IL255433B2 (en) (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
JP6321825B2 (ja) 神経形成を刺激することができるｎ−フェニル−ラクタム誘導体及び神経障害の処置におけるそれらの使用
JP2010138190A5 (enExample)
SI8310672A8 (en) Process for the production of cis-4-fenil-1,2,3,4-tetrahydro-1-naphthylamine derivates.
JP7265990B2 (ja) 神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体
JP4198989B2 (ja) セロトニン作動性薬
JP2005539068A5 (enExample)
JP2009527462A5 (enExample)
JP2022502500A5 (enExample)
JP2022515293A5 (enExample)
JP2001511131A (ja) 月経前不快障害の処置
JP2019529460A5 (enExample)
JP2022541938A5 (enExample)
JP2013530953A5 (enExample)
JP2013526596A5 (enExample)
JP2022539152A5 (enExample)
JP2024531437A5 (enExample)
JP2014518552A5 (enExample)
JP2008538582A (ja) 精神病性障害の治療または予防のための新規の治療的組み合わせ
JPH06500099A (ja) Ｃｎｓ疾病の処置におけるヘテロ環状アミノ―アルコール化合物の使用
JP2022048978A5 (ja) ケンペロール配糖体化合物を含む、老化により増殖が抑制された皮膚細胞の増殖を誘導するための組成物
JP2007530703A5 (enExample)